Engineering Sonogenetic EchoBack-CAR T cells
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1222799 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR32323138_1.fastq.gz | Fastqsanger.gz | |||
| SRR32323138_2.fastq.gz | Fastqsanger.gz | |||
| SRR32323139_1.fastq.gz | Fastqsanger.gz | |||
| SRR32323139_2.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 4 of 4 |
Similar Datasets
Project description:Chimeric antigen receptor (CAR) T cell therapy marks a significant advancement in oncology, offering the promise of durable remissions in hematological malignancies. However, solid tumors present formidable challenges, including on-target off-tumor toxicity, exhaustion, and limited persistence of therapeutic T cells. Here, we engineered sonogenetic EchoBack-CAR T cells using a highly heat-sensitive promoter, evolved through a sort-seq platform, and integrated it with a positive feedback loop from CAR signaling pathways that enables the conversion of tumor engagement into CAR production, resulting in long-lasting CAR expression upon remote stimulation by focused ultrasound (FUS). EchoBack-CAR T cells with a high-affinity single-chain variable fragment (scFv) targeting disialoganglioside GD2 (EchoBack-hGD2CAR) exhibited potent cytotoxicity and persistence in an in vitro glioblastoma spheroid model. In both subcutaneous and orthotopic glioblastoma models in mice, EchoBack-hGD2CAR T cells achieved robust and safe tumor suppression without off-tumor toxicity. Through single-cell RNA sequencing, we uncovered a distinctive transcriptomic landscape that underscores the enhanced cytotoxicity and reduced exhaustion of EchoBack-CAR T cells after chronic antigen stimulation compared to standard CAR T cells that constitutively express CAR. The EchoBack-CAR can also be generalized and extended to treat prostate cancer by targeting prostate-specific membrane antigen (EchoBack-PSMACAR), demonstrating a remarkable tumor suppression but minimal off-tumor toxicity to healthy tissues. Collectively, these findings not only highlight the potential of EchoBack-CAR T cells to promote solid tumor immunotherapy via ultrasound remote control but also present a modular approach adaptable to various cancer targets, poised to mitigate the limitations of current CAR T cell therapies.
2025-05-29 | GSE289368 | GEO
Project description:Chimeric antigen receptor T cells (CAR-Ts) are transformative cellular therapies; however, current forms of CAR-T face multiple major hurdles. These include antigen loss, tumor microenvironment suppression, trafficking, proliferation, toxicity, and persistence. An efficient way to overcome these challenges is to engineer thousands of different CAR-T variants, and systematically select the best ones. To achieve this, we develop CLASH, a versatile platform that enables high-efficiency massively parallel CAR-T engineering. In CLASH, pooled AAVs mediate simultaneous gene editing and precise CAR knock-in via massively parallel homology-directed repair (HDR). Such library-scale HDR events produce a pool of stably integrated CAR-T variants each with targeted immune gene editing. In vitro or in vivo CLASH experiments using human CD8 and CD4 T cells subject the CAR-T pools to long-term co-culture or animal models of cancer, enabling unbiased selection of favorable CAR-T variants with enhanced cancer killing and persistence. Next-generation sequencing of genomic integrations deconvolves the time-course dynamics of knock-in CAR-T variants and identify winning CAR-Ts that survived specific selections. Validations of convergent top genes JADE1, PELI1, EHMT1, NLRP10, KDM4E, TET2 and PRDM1 show that their perturbations in CAR-Ts modulate T cell characteristics such as proliferation, exhaustion and memory phenotypes. A PRDM1 exon3-skip mutant CAR-T exhibits increased proliferation capacity, central memory cell phenotype and longevity, resulting in high-performance in vivo therapeutic efficacy in adoptive cell therapy models across multiple cancer models including solid tumor. Time-course transcriptomics and immune profiling and molecular interrogations demonstrate that PRDM1 exon3-skip CAR-Ts have multiple rewired gene expression patterns and immunological programs. Interrogations of the epigenetic mechanism via histone array, co-immunoprecipitation and genome-wide chromatin binding by Cut-and-Run reveal that deletion of exon-3 leads to disruption of histone H4 binding to the PR domain, thereby altering the regulation of critical downstream immune factors including SELL, CCR7, STAT1, STAT6, CDCA7 and IL7R. The versatility of CLASH is broadly applicable to the engineering of various desired CAR features in a wide range of cell therapies.
2022-12-09 | GSE201997 | GEO
Project description:This study generated ErbB2-specific CAR-T and CAR-CIK (cytokine induced killer) cells from peripheral blood mononuclear cells by lentiviral transduction. Transduced and untransduced parental cells were co-incubated with the human rhabomyosarcoma cell line Rh30 for 24 hours, harvested and washed twice. CD45+ (CD45PacificBlue, BioLegend) effector cells were isolated via FACS (BD FACS Aria 3), spun down and stored at -80 °C for analysis via LS-MS.
2025-01-31 | PXD050654 | Pride
Project description:The study aimed to elucidate the transcriptional changes introduced by genetic engineering of CAR T cells to stably express the homeostatic chemokine receptor CCR7. In vitro killing assays hinted to a higher cytolytic capacity that could be tied to an altered cytoskeletal rearrangement. Human CAR and CAR.CCR7 T cells were generated by retroviral transduction and enriched by FACS at the end of the expansion phase (day 10), either without or with a previous over-night co-culture with target Jeko1 tumor cells that express the CAR target antigen CXCR5. Enriched cells were immediately processed for bulk mRNA Seq
2023-06-30 | E-MTAB-12778 | biostudies-arrayexpress
Project description:Massively parallel engineering of persistent CAR-Ts
| PRJNA833968 | ENA
Project description:Massively parallel engineering of persistent CAR-Ts
| PRJNA906963 | ENA
Project description:Due to the low-throughput process of systematically designing and functionally testing chimeric antigen receptors (CARs), only a small set of immune signaling domains have been thoroughly explored, despite their major role in T cell activation, effector function and persistence. SpeedingCARs presents an integrated method for engineering CAR T cells by signaling domain shuffling and functional screening by single-cell sequencing. Leveraging the inherent modularity of natural signaling domains, we generated a diverse library of 180 unique CAR variants, which were genomically integrated into primary human T cells by CRISPR-Cas9. Functional and pooled screening of the CAR T cell library was performed by co-culture with tumor cells, followed by single-cell RNA sequencing (scRNA-seq) and single-cell CAR sequencing (scCAR-seq), thus enabling high-throughput profiling of multi-dimensional cellular responses.
2022-10-03 | GSE214231 | GEO
Project description:Massively parallel engineering of persistent CAR-Ts [GEO_CLASH_Nextera]
| PRJNA906967 | ENA
Project description:Massively parallel engineering of persistent CAR-Ts [GEO_CLASH_MIPS]
| PRJNA906968 | ENA
Project description:Massively parallel engineering of persistent CAR-Ts [XDRNA]
| PRJNA855251 | ENA